BCL2 and plasma cell myeloma: According to the literature, myeloma cells bearing t(11;14) translocation have lower oxygen consumption rates than myeloma cells without this translocation28 and are more sensitive to Bcl-2 inhibitor ABT-199 (venetoclax)29,30.